GPHD
This trial compares the efficacy and safety of tirzepatide once weekly at either 5 mg, 10 mg, 15 mg dose to 3 times a day Lispro in patients with type 2 diabetes on glargine.

Type of Study:
Parallel treatment study with 4 arms no masking.

Study Length:
26 Weeks

Target Age/Sex:
over 18 years, Male and Female

Benefits:
Participants will receive at no cost: study product, study materials and study-specific procedures

Link: ClinicalTrials.gov

Staus: Closed

Description:

This trial compares the efficacy and safety of tirzepatide once weekly at either 5 mg, 10 mg, 15 mg dose to 3 times a day Lispro in patients with type 2 diabetes on glargine.

This Study is Closed.